Benfluorex and unexplained valvular heart disease: A case-control study

PLoS ONE

Volumn 5, Issue 4, 2010, Pages 1-5

  Frachon, Irène ^a,b,c   Etienne, Yves ^c   Jobic, Yannick ^c   Le Gal, Grégoire ^a,d   Humbert, Marc ^e,f,g   Leroyer, Christophe ^a,b,c  

^a UNIVERSITÉ EUROPÉENNE DE BRETAGNE   (France)

^b UNIVERSITÉ DE BRETAGNE OCCIDENTALE   (France)

^c SERVICE DE RHUMATOLOGIE   (France)

^d Centre d'Investigation Clinique   (France)

^e UNIVERSITÉ PARIS SACLAY   (France)

^f HÔPITAL ANTOINE BÉCLÈRE   (France)

^g Universite Paris Sud   (France)

Author keywords

[No Author keywords available]

Indexed keywords

BENFLUOREX; DEXFENFLURAMINE; ANTILIPEMIC AGENT; DRUG DERIVATIVE; FENFLURAMINE;

ADULT; ARTICLE; BODY MASS; CASE CONTROL STUDY; CLINICAL ARTICLE; CONTROLLED STUDY; DIABETES MELLITUS; DRUG EXPOSURE; FEMALE; FRANCE; HUMAN; MALE; MITRAL VALVE REGURGITATION; RETROSPECTIVE STUDY; VALVULAR HEART DISEASE; AGED; CHEMICALLY INDUCED DISORDER; MIDDLE AGED; RISK; SINGLE BLIND PROCEDURE;

AGED; CASE-CONTROL STUDIES; FEMALE; FENFLURAMINE; HEART VALVE DISEASES; HUMANS; HYPOLIPIDEMIC AGENTS; MALE; MIDDLE AGED; MITRAL VALVE INSUFFICIENCY; ODDS RATIO; RETROSPECTIVE STUDIES; SINGLE-BLIND METHOD;

EID: 77956327489     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0010128     Document Type: Article

References (19)

1. Abenhaim L, Moride Y, Brenot F, Rich S, Benichou J, et al. (1196) Appetitesuppressant drugs and the risk of primary pulmonary hypertension. International Primary Pulmonary Hypertension Study Group. N Engl J Med 335: 609-616.
2. Connolly HM, Crary JL, McGoon MD, Hensrud DD, Edwards BS, et al. (1997) Valvular heart disease associated with fenfluramine-phentermine. N Engl J Med 337: 581-8.
3. Roth BL (2007) Drugs and valvular heart disease. N Engl J Med 356: 6-9.
4. Boutet K, Frachon I, Jobic Y, Gut-Gobert C, Leroyer C, et al. (2009) Fenfluramine-like cardiovascular side-effects of benfluorex. Eur Respir J 33: 684-8.
5. Duhault J, Malen C (1970) Effect of a fenfluramine derivative (S 992) on lipid and sugar metabolism. In: Costa E, Garattini S, eds. Amphetamines and related compounds. New-York: Raven Press. pp 619-626.
6. Rafel Ribera J, Casanas Munoz R, Anguera Ferrando N, Batalla Sahun N, Castro Cels A, et al. (2003) Valvular heart disease associated with benfluorex. Rev Esp Cardiol 56: 215-6.
7. Noize P, Sauer M, Bruneval P, Moreau M, Pathak A, et al. (2006) Valvular heart disease in a patient taking benfluorex. Fundam Clin Pharmacol 20: 577-8.
8. Dahl CF, Allen MR, Urie PM, Hopkins PN (2008) Valvular regurgitation and surgery associated with fenfluramine use: an analysis of 5743 individuals. BMC Med 6: 34-46.
9. Singh JP, Evans JC, Levy D, Larson MG, Freed LA, et al. (1999) Prevalence and clinical determinants of mitral, tricuspid, and aortic regurgitation (the Framingham Heart Study). Am J Cardiol 83: 897-902.
10. Enriquez-Sarano M, Atkins CW, Vahanian A (2009) Mitral regurgitation. Lancet 373: 1382-1194.
11. Jick H, Vasilakis C, Weinrauch LA, Meier CR, Jick SS, et al. (1998) A population-based study of appetite-suppressant drugs and the risk of cardiacvalve regurgitation. N Engl J Med 339: 719-724.
12. Khan MA, Herzog CA, St Peter JV, Hartley GG, Madlon-Kay R, et al. (1988) The prevalence of cardiac valvular insufficiency assessed by transthoracic echocardiography in obese patients treated with appetite-suppressant drugs. N Engl J Med 339: 713-718.
13. Weissman NJ, Tighe JF, Jr., Gottdiener JS, Gwynne JT (1998) An assessment of heart-valve abnormalities in obese patients taking dexfenfluramine, sustainedrelease dexfenfluramine, or placebo. Sustained-Release Dexfenfluramine Study Group. N Engl J Med 339: 725-32.
14. Pritchett AM, Morrison JF, Edwards WD, Schaff HV, Connolly HM, et al. (2002) Valvular heart disease in patients taking pergolide. Mayo Clin Proc 77: 1280-6.
15. Schade R, Andersohn F, Suissa S, Haverkamp W, Garbe E (2007) Dopamine agonists and the risk of cardiac-valve regurgitation. N Engl J Med 356: 29-38.
16. Zanettini R, Antonini A, Gatto G, Gentile R, Tesei S, et al. (2007) Valvular heart disease and the use of dopamine agonists for Parkinson's disease. N Engl J Med 356: 39-46.
17. Rothman RB, Baumann MH, Savage JE, Rauser L, McBride A, et al. (2000) Evidence for possible involvement of 5-HT(2B) receptors in the cardiacvalvulopathy associated with fenfluramine and other serotonergic medications. Circulation 102: 2836-41.
18. Bhattacharyya S, Schapira AH, Mikhailidis DP, Davar J (2009) Drug-induced fibrotic valvular heart disease. Lancet 374: 577-85.
19. AFSSAPS (2009) Suspension d'autorisation de mise sur le marché des médicaments contenant du benfluorex-communiqué. Available: http://www.afssaps.fr/Infos-de-securite/Communiques-de-presse/Suspension-d-autorisationde-mise-sur-le-marche-des-medicaments-contenant-du-benfluorex-communique. Accessed 2009 Dec 27.